Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
时间:2024-06-16 17:56:04 阅读(143)
Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2 percent.
The approval has been granted to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc. The product will be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Suspension, 0.2% (RLD Alrex), had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).
分享到:
温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!
猜你喜欢
- Sebi to auction 61 properties of Saradha Group on July 17 to recover investors’ money
- TVS Motor, VPRP, Senco Gold, IFCI among 51 stocks that hit 14-week highs; 9 slip to 52-week lows
- Sensex, Nifty open in red on Wednesday; Rail Vikas Nigam shares rise 4%, Punjab Sind Bank shares up over 1%
- Top 5 cloud computing trends to look for 2024
- Sebi’s new disclosure norms for listed companies to kick in from Saturday
- No requiem for the village, yet- An enlightening tale of the Indian village, with resilience of the rural as the central theme
- Sensex zooms past 60000; Nifty ends near 17950, next target seen at 18175, here’s what analysts say
- Titan, ONGC among top technical stocks to buy, charts show strength; Nifty support at 16850
- The use of artificial intelligence in combatting financial crimes